Skip to main content

Table 3 Multivariable association of A) QoL at last available follow-up and B) change in QoL between Baseline and last available follow-up and clinical characteristics with mortality

From: The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry

 

SGRQ total

EQ-5D VAS

UCSD-SOBQ

WHO-5

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

HR

95% CI

p-value

A) Multivariable model including QoL at last available follow-up

 QoL at last available follow-up a

1.12

1.06; 1.18

< 0.001

0.91

0.87; 0.96

0.001

1.14

1.08; 1.20

< 0.001

0.83

0.69; 0.99

0.048

 Age a

1.32

1.14; 1.54

< 0.001

1.30

1.12; 1.51

0.001

1.27

1.09; 1.48

0.002

1.25

1.07; 1.46

0.006

 Number of comorbidities

  0

1.00

  

1.00

  

1.00

  

1.00

  

  1

2.40

1.15; 5.01

0.02

1.93

0.98; 3.77

0.057

2.51

0.92; 6.81

0.071

2.03

0.93; 4.41

0.075

  2

2.10

1.02; 4.32

0.043

1.62

0.83; 3.19

0.161

2.40

0.90; 6.40

0.079

2.24

1.05; 4.80

0.038

  3

2.78

1.26; 6.09

0.011

2.15

1.02; 4.53

0.043

3.16

0.99; 10.05

0.052

2.31

0.97; 5.46

0.057

  4+

1.95

0.69; 5.49

0.205

1.98

0.77; 5.07

0.155

1.30

0.29; 5.86

0.734

2.80

1.00; 7.86

0.051

 Change in FVC % predicted

  Stable/increase

1.00

  

1.00

  

1.00

  

1.00

  

  Decrease by 0 to 10%

1.63

0.98; 2.71

0.058

1.60

0.97; 2.64

0.066

1.41

0.75; 2.64

0.286

1.75

1.01; 3.03

0.047

  Decrease by > 10%

2.34

1.18; 4.62

0.015

2.29

1.16; 4.51

0.017

2.14

0.87; 5.26

0.096

2.70

1.32; 5.53

0.007

 Hospitalisation

1.26

0.80; 1.97

0.322

1.54

0.98; 2.40

0.06

1.00

0.57; 1.74

0.994

1.29

0.81; 2.06

0.286

 Overall physician’s judgement of clinical course of IPF

  Stable disease

1.00

  

1.00

  

1.00

  

1.00

  

  Slow progression

1.48

0.92; 2.38

0.106

1.70

1.08; 2.69

0.022

1.30

0.71; 2.37

0.399

1.91

1.16; 3.17

0.012

  Rapid progression

0.97

0.46; 2.04

0.933

1.18

0.55; 2.53

0.674

1.06

0.46; 2.42

0.896

1.25

0.53; 2.95

0.617

  No judgement possible

0.89

0.46; 1.74

0.743

0.98

0.52; 1.84

0.95

1.26

0.54; 2.93

0.588

0.94

0.47; 1.91

0.871

B) Multivariable model including change in QoL between baseline and last available follow-up

 Change in QoL between baseline and last available follow-up a

1.05

0.98; 1.13

0.148

0.97

0.91; 1.04

0.364

1.07

0.98; 1.16

0.127

0.85

0.68; 1.07

0.165

 Age a

1.30

1.11; 1.52

0.001

1.31

1.12; 1.53

0.001

1.26

1.02; 1.56

0.031

1.26

1.07; 1.48

0.006

 Number of comorbidities

  0

1.00

  

1.00

  

1.00

  

1.00

  

  1

1.98

0.97; 4.04

0.061

1.83

0.92; 3.63

0.084

2.03

0.71; 5.84

0.187

1.93

0.89; 4.20

0.096

  2

1.85

0.90; 3.79

0.092

1.70

0.85; 3.40

0.135

2.01

0.65; 6.21

0.226

2.14

0.99; 4.63

0.054

  3

2.40

1.10; 5.24

0.028

2.25

1.06; 4.76

0.035

3.68

1.17; 11.55

0.026

2.18

0.91; 5.23

0.082

  4+

2.04

0.75; 5.57

0.165

2.27

0.87; 5.92

0.093

1.54

0.26; 9.06

0.634

2.99

1.09; 8.22

0.034

 Change in FVC % predicted

  Stable/increase

1.00

  

1.00

  

1.00

  

1.00

  

  Decrease by 0 to 10%

1.69

1.02; 2.82

0.044

1.65

0.99; 2.76

0.055

1.11

0.57; 2.14

0.762

1.67

0.95; 2.91

0.073

  Decrease by > 10%

2.16

1.08; 4.31

0.029

2.26

1.14; 4.50

0.02

1.72

0.71; 4.14

0.227

2.43

1.18; 5.00

0.015

 Hospitalisation

1.35

0.85; 2.13

0.202

1.54

0.98; 2.42

0.059

1.30

0.68; 2.45

0.427

1.30

0.81; 2.08

0.285

 Overall physician’s judgement of clinical course of IPF

  Stable disease

1.00

  

1.00

  

1.00

  

1.00

  

  Slow progression

1.69

1.05; 2.73

0.03

1.83

1.14; 2.94

0.012

1.38

0.67; 2.85

0.381

1.89

1.15; 3.12

0.013

  Rapid progression

1.42

0.69; 2.91

0.341

1.63

0.76; 3.46

0.207

1.27

0.47; 3.41

0.636

1.38

0.61; 3.12

0.439

  No judgement possible

0.97

0.49; 1.92

0.922

0.96

0.50; 1.83

0.902

1.24

0.52; 2.95

0.622

0.83

0.39; 1.77

0.635

  1. CI confidence interval, EQ-5D VAS EuroQol five-dimensional questionnaire, recorded as a visual analog scale, HR hazard ratio, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, QoL quality of life, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire, USCD-SOBQ University of California San Diego Shortness of Breath Questionnaire, WHO-5 World Health Organization-5 Well-Being Index
  2. a HR for increase by 5 points on the QoL scale or by 5 years of age